The Microbiome and Primary Sclerosing Cholangitis

Ahmad H. Ali, Elizabeth J. Carey, Keith Lindor

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with detrimental sequela. In many patients, PSC progresses to end-stage liver disease and hepatobiliary cancer. There is no medical therapy that is proven to halt or reverse the progression of PSC. Approximately 70 to 80% of PSC patients have inflammatory bowel disease, usually ulcerative colitis. The etiology of PSC is poorly understood. Several lines of evidence suggest that the intestinal microbiota plays an important role in the etiopathogenesis of PSC. Stemming from this theory, several antibiotics have been tried in PSC, some of which had shown promising results. Fecal microbiota transplantation is a novel therapy, and is currently being investigated as a potential therapeutic strategy in PSC along with probiotics. In this article, the authors discuss the current knowledge of the intestinal microbiota in PSC.

Original languageEnglish (US)
Pages (from-to)340-348
Number of pages9
JournalSeminars in Liver Disease
Volume36
Issue number4
DOIs
StatePublished - Sep 1 2016

Fingerprint

Sclerosing Cholangitis
Microbiota
End Stage Liver Disease
Probiotics
Ulcerative Colitis
Inflammatory Bowel Diseases
Liver Diseases
Therapeutics
Anti-Bacterial Agents

Keywords

  • antibiotics
  • genome-wide association studies
  • microbiota
  • primary sclerosing cholangitis

ASJC Scopus subject areas

  • Hepatology

Cite this

The Microbiome and Primary Sclerosing Cholangitis. / Ali, Ahmad H.; Carey, Elizabeth J.; Lindor, Keith.

In: Seminars in Liver Disease, Vol. 36, No. 4, 01.09.2016, p. 340-348.

Research output: Contribution to journalArticle

Ali, Ahmad H. ; Carey, Elizabeth J. ; Lindor, Keith. / The Microbiome and Primary Sclerosing Cholangitis. In: Seminars in Liver Disease. 2016 ; Vol. 36, No. 4. pp. 340-348.
@article{2e83f8bbaa9a4b01aad72fa48fd561bc,
title = "The Microbiome and Primary Sclerosing Cholangitis",
abstract = "Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with detrimental sequela. In many patients, PSC progresses to end-stage liver disease and hepatobiliary cancer. There is no medical therapy that is proven to halt or reverse the progression of PSC. Approximately 70 to 80{\%} of PSC patients have inflammatory bowel disease, usually ulcerative colitis. The etiology of PSC is poorly understood. Several lines of evidence suggest that the intestinal microbiota plays an important role in the etiopathogenesis of PSC. Stemming from this theory, several antibiotics have been tried in PSC, some of which had shown promising results. Fecal microbiota transplantation is a novel therapy, and is currently being investigated as a potential therapeutic strategy in PSC along with probiotics. In this article, the authors discuss the current knowledge of the intestinal microbiota in PSC.",
keywords = "antibiotics, genome-wide association studies, microbiota, primary sclerosing cholangitis",
author = "Ali, {Ahmad H.} and Carey, {Elizabeth J.} and Keith Lindor",
year = "2016",
month = "9",
day = "1",
doi = "10.1055/s-0036-1594007",
language = "English (US)",
volume = "36",
pages = "340--348",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - The Microbiome and Primary Sclerosing Cholangitis

AU - Ali, Ahmad H.

AU - Carey, Elizabeth J.

AU - Lindor, Keith

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with detrimental sequela. In many patients, PSC progresses to end-stage liver disease and hepatobiliary cancer. There is no medical therapy that is proven to halt or reverse the progression of PSC. Approximately 70 to 80% of PSC patients have inflammatory bowel disease, usually ulcerative colitis. The etiology of PSC is poorly understood. Several lines of evidence suggest that the intestinal microbiota plays an important role in the etiopathogenesis of PSC. Stemming from this theory, several antibiotics have been tried in PSC, some of which had shown promising results. Fecal microbiota transplantation is a novel therapy, and is currently being investigated as a potential therapeutic strategy in PSC along with probiotics. In this article, the authors discuss the current knowledge of the intestinal microbiota in PSC.

AB - Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with detrimental sequela. In many patients, PSC progresses to end-stage liver disease and hepatobiliary cancer. There is no medical therapy that is proven to halt or reverse the progression of PSC. Approximately 70 to 80% of PSC patients have inflammatory bowel disease, usually ulcerative colitis. The etiology of PSC is poorly understood. Several lines of evidence suggest that the intestinal microbiota plays an important role in the etiopathogenesis of PSC. Stemming from this theory, several antibiotics have been tried in PSC, some of which had shown promising results. Fecal microbiota transplantation is a novel therapy, and is currently being investigated as a potential therapeutic strategy in PSC along with probiotics. In this article, the authors discuss the current knowledge of the intestinal microbiota in PSC.

KW - antibiotics

KW - genome-wide association studies

KW - microbiota

KW - primary sclerosing cholangitis

UR - http://www.scopus.com/inward/record.url?scp=85006868969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006868969&partnerID=8YFLogxK

U2 - 10.1055/s-0036-1594007

DO - 10.1055/s-0036-1594007

M3 - Article

VL - 36

SP - 340

EP - 348

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -